Compare TFPM & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TFPM | SRRK |
|---|---|---|
| Founded | 2016 | 2012 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 5.2B |
| IPO Year | 2022 | 2018 |
| Metric | TFPM | SRRK |
|---|---|---|
| Price | $27.74 | $50.40 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 18 |
| Target Price | $39.25 | ★ $70.06 |
| AVG Volume (30 Days) | 404.0K | ★ 1.5M |
| Earning Date | 11-03-2026 | 11-10-2026 |
| Dividend Yield | ★ 0.83% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $26.92 | N/A |
| Revenue Next Year | $17.67 | $616.55 |
| P/E Ratio | $35.57 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $26.61 | $38.02 |
| 52 Week High | $41.70 | $61.76 |
| Indicator | TFPM | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 36.85 | 62.00 |
| Support Level | $27.21 | $45.11 |
| Resistance Level | $31.86 | $50.56 |
| Average True Range (ATR) | 1.00 | 2.79 |
| MACD | -0.20 | 0.49 |
| Stochastic Oscillator | 0.28 | 80.04 |
Triple Flag Precious Metals Corp is a streaming and royalty company focused on precious metals. Its revenues are largely generated from a diversified portfolio of properties in Australia, Canada, Colombia, Cote d'Ivoire, Mexico, Mongolia, Peru, South Africa, and the United States. Its diversified portfolio of streams and royalties comprises long-life mining assets, including the Northparkes copper-gold mine in Australia, the Cerro Lindo polymetallic mine in Peru, the Fosterville gold mine in Australia, the Buritica gold mine in Colombia, and the Impala Bafokeng Operations in South Africa among others. A majority of its revenue is derived through its interests in various gold streams. Geographically, the company derives maximum revenue from Australia, followed by Peru and other regions.
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.